Intervention Protocol

Propionyl-L-carnitine for intermittent claudication

  1. Tine LM de Backer1,*,
  2. Laurence Campens2,
  3. Robert Vander Stichele3,
  4. Luc Van Bortel3,
  5. Dirk De Bacquer4

Editorial Group: Cochrane Peripheral Vascular Diseases Group

Published Online: 12 SEP 2012

DOI: 10.1002/14651858.CD010117

How to Cite

de Backer TLM, Campens L, Vander Stichele R, Van Bortel L, De Bacquer D. Propionyl-L-carnitine for intermittent claudication (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010117. DOI: 10.1002/14651858.CD010117.

Author Information

  1. 1

    Heart Center, Ghent University Hospital and the Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium

  2. 2

    Ghent University, Ghent, Belgium

  3. 3

    Ghent University, Heymans Institute of Clinical Pharmacology, Ghent, Belgium

  4. 4

    Ghent University, Department of Public Health, Ghent, Belgium

*Tine LM de Backer, Heart Center, Ghent University Hospital and the Heymans Institute of Pharmacology, Ghent University, De Pintelaan 185, Ghent, B-9000, Belgium. tine.debacker@ugent.be. t_de_backer@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 12 SEP 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to determine whether propionyl-L-carnitine is efficacious compared with placebo, other active drugs or with any other intervention for intermittent claudication (exercise, angioplasty, surgery) in increasing pain-free and maximum walking distance for patients with stable intermittent claudication, Fontaine stage II.